

Randy Quentin Cron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8455189/publications.pdf>

Version: 2024-02-01

175
papers

10,497
citations

31976

53
h-index

36028

97
g-index

181
all docs

181
docs citations

181
times ranked

9393
citing authors

#	ARTICLE	IF	CITATIONS
1	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011, 63, 465-482.	3.4	658
2	On the Alert for Cytokine Storm: Immunopathology in COVID-19. <i>Arthritis and Rheumatology</i> , 2020, 72, 1059-1063.	5.6	562
3	The Immunology of Macrophage Activation Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 119.	4.8	448
4	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	5.6	427
5	Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. <i>Arthritis and Rheumatism</i> , 2011, 63, 545-555.	6.7	397
6	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.9	338
7	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 3160-3169.	5.6	322
8	MHCII Is Required for α -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration. <i>Journal of Neuroscience</i> , 2013, 33, 9592-9600.	3.6	304
9	Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1133-8.	2.0	245
10	Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. <i>Rheumatology</i> , 2011, 50, 417-419.	1.9	238
11	High prevalence of temporomandibular joint arthritis at disease onset in children with juvenile idiopathic arthritis, as detected by magnetic resonance imaging but not by ultrasound. <i>Arthritis and Rheumatism</i> , 2008, 58, 1189-1196.	6.7	221
12	Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 326-334.	5.6	197
13	Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. <i>Lancet Rheumatology</i> , The, 2020, 2, e358-e367.	3.9	197
14	Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 486.	3.5	176
15	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 764-768.	2.0	140
16	Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. <i>Journal of Infectious Diseases</i> , 2016, 213, 1180-1188.	4.0	133
17	Treatment of juvenile idiopathic arthritis: a revolution in care. <i>Pediatric Rheumatology</i> , 2014, 12, 13.	2.1	125
18	Emergent high fatality lung disease in systemic juvenile arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1722-1731.	0.9	122

#	ARTICLE	IF	CITATIONS
19	Temporomandibular joint arthritis in juvenile idiopathic arthritis: the forgotten joint. <i>Current Opinion in Rheumatology</i> , 2006, 18, 490-495.	4.3	121
20	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 927-941.	2.2	121
21	NFAT1 Enhances HIV-1 Gene Expression in Primary Human CD4 T Cells. <i>Clinical Immunology</i> , 2000, 94, 179-191.	3.2	115
22	Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). <i>Journal of Rheumatology</i> , 2008, 35, 343-8.	2.0	114
23	Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3563-3569.	6.7	113
24	Genetic Defects in Cytolysis in Macrophage Activation Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 439.	4.7	113
25	Regulation of the Murine Nfatc1 Gene by NFATc2. <i>Journal of Biological Chemistry</i> , 2002, 277, 10704-10711.	3.4	111
26	Risk Factors for Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1880-1887.	2.0	106
27	Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2220-2227.	6.7	105
28	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101
29	The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic. <i>Pediatric Rheumatology</i> , 2009, 7, 11.	2.1	99
30	Calming the cytokine storm in COVID-19. <i>Nature Medicine</i> , 2021, 27, 1674-1675.	30.7	97
31	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 409-419.	3.4	96
32	High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. <i>Pediatric Rheumatology</i> , 2014, 12, 26.	2.1	90
33	The Rheumatologist's Role in COVID-19. <i>Journal of Rheumatology</i> , 2020, 47, 639-642.	2.0	90
34	Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. <i>Paediatric Drugs</i> , 2020, 22, 29-44.	3.1	85
35	The Human gp39 Promoter. <i>Journal of Biological Chemistry</i> , 1995, 270, 29624-29627.	3.4	81
36	Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 180-181.	2.0	78

#	ARTICLE	IF	CITATIONS
37	Intra-Articular Corticosteroid Injections to the Temporomandibular Joints Are Safe and Appear to Be Effective Therapy in Children With Juvenile Idiopathic Arthritis. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 1802-1807.	1.2	77
38	A Heterozygous <i>RAB27A</i> Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. <i>Journal of Immunology</i> , 2016, 196, 2492-2503.	0.8	77
39	Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression. <i>Molecular and Cellular Biology</i> , 2003, 23, 510-525.	2.3	75
40	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.9	74
41	Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what?. <i>Pediatric Rheumatology</i> , 2018, 16, 32.	2.1	72
42	Clinical Orofacial Examination in Juvenile Idiopathic Arthritis: International Consensus-based Recommendations for Monitoring Patients in Clinical Practice and Research Studies. <i>Journal of Rheumatology</i> , 2017, 44, 326-333.	2.0	69
43	Treatment of pediatric localized scleroderma with methotrexate. <i>Journal of Rheumatology</i> , 2006, 33, 609-14.	2.0	68
44	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 553-569.	5.6	68
45	Rituximab Therapy for Severe Refractory Chronic Henoch-SchÅ¶nlein Purpura. <i>Journal of Pediatrics</i> , 2009, 155, 136-139.	1.8	64
46	The genetics of macrophage activation syndrome. <i>Genes and Immunity</i> , 2020, 21, 169-181.	4.1	64
47	Clinical features and correct diagnosis of macrophage activation syndrome. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1043-1053.	3.0	60
48	Imaging of the Temporomandibular Joint in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 47-54.	3.4	59
49	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 994-1001.	2.0	59
50	Age and fecal microbial strain-specific differences in patients with spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 14.	3.5	58
51	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	3.8	57
52	High Doses of Infliximab in the Management of Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1749-1755.	2.0	56
53	Successful treatment of pediatric IgG4 related systemic disease with mycophenolate mofetil: case report and a review of the pediatric autoimmune pancreatitis literature. <i>Pediatric Rheumatology</i> , 2011, 9, 1.	2.1	55
54	Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome. <i>Journal of Rheumatology</i> , 2013, 40, 743-744.	2.0	53

#	ARTICLE	IF	CITATIONS
55	Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. <i>Journal of Rheumatology</i> , 2006, 33, 2081-4.	2.0	52
56	CT-Guided Percutaneous Steroid Injection for Management of Inflammatory Arthropathy of the Temporomandibular Joint in Children. <i>American Journal of Roentgenology</i> , 2007, 188, 182-186.	2.2	50
57	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	1.8	50
58	The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28581.	1.5	50
59	Attainment of Inactive Disease Status Following Initiation of TNF-Î± Inhibitor Therapy for Juvenile Idiopathic Arthritis: Enthesitis-related Arthritis Predicts Persistent Active Disease. <i>Journal of Rheumatology</i> , 2011, 38, 2675-2681.	2.0	48
60	Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 345-349.	2.1	47
61	The Î³c-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. <i>Virology</i> , 2006, 344, 283-291.	2.4	46
62	Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2015, 42, 541-546.	2.0	46
63	Toward Establishing a Standardized Magnetic Resonance Imaging Scoring System for Temporomandibular Joints in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 758-767.	3.4	46
64	Standardizing Terminology and Assessment for Orofacial Conditions in Juvenile Idiopathic Arthritis: International, Multidisciplinary Consensus-based Recommendations. <i>Journal of Rheumatology</i> , 2019, 46, 518-522.	2.0	43
65	Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. <i>Journal of Pediatrics</i> , 1998, 132, 901-902.	1.8	42
66	CD154 Transcriptional Regulation in Primary Human CD4 T Cells. <i>Immunologic Research</i> , 2003, 27, 185-202.	2.9	42
67	The impact of NucleofectionÂ® on the activation state of primary human CD4 T cells. <i>Journal of Immunological Methods</i> , 2014, 408, 123-131.	1.4	42
68	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 716-737.	1.3	40
69	Highways to hell: Mechanism-based management of cytokine storm syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 949-959.	2.9	39
70	COVID-19 cytokine storm: targeting the appropriate cytokine. <i>Lancet Rheumatology</i> , The, 2021, 3, e236-e237.	3.9	39
71	FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity. <i>Virology</i> , 2008, 381, 161-167.	2.4	38
72	Decreased CD154 expression by neonatal CD4+ T cells is due to limitations in both proximal and distal events of T cell activation. <i>International Immunology</i> , 2003, 15, 1461-1472.	4.0	37

#	ARTICLE	IF	CITATIONS
73	Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. <i>Pediatric Radiology</i> , 2007, 37, 544-548.	2.0	37
74	FOXP3 Inhibits Activation-Induced NFAT2 Expression in T Cells Thereby Limiting Effector Cytokine Expression. <i>Journal of Immunology</i> , 2009, 183, 907-915.	0.8	37
75	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	5.6	36
76	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	3.9	36
77	Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg. <i>European Journal of Rheumatology</i> , 2020, 7, 13-20.	0.6	36
78	Safety and efficacy of intra-articular infliximab therapy for treatment-resistant temporomandibular joint arthritis in children: a retrospective study. <i>Rheumatology</i> , 2013, 52, 554-559.	1.9	35
79	Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. <i>Pediatric Rheumatology</i> , 2018, 16, 71.	2.1	34
80	Effectiveness and Toxicity of Methotrexate in Juvenile Idiopathic Arthritis: Comparison of 2 Initial Dosing Regimens. <i>Journal of Rheumatology</i> , 2010, 37, 870-875.	2.0	33
81	Isolated Arthritis of the Temporomandibular Joint as the Initial Manifestation of Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1632-1635.	2.0	33
82	Brief Report: Novel <i>UNC13D</i> Intronic Variant Disrupting an NF- κ B Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 963-970.	5.6	30
83	Risk Factors for Intraarticular Heterotopic Bone Formation in the Temporomandibular Joint in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1301-1307.	2.0	30
84	Distinguishing active pediatric COVID-19 pneumonia from MIS-C. <i>Pediatric Rheumatology</i> , 2021, 19, 21.	2.1	30
85	A T Cell-specific Enhancer of the Human CD40 Ligand Gene. <i>Journal of Biological Chemistry</i> , 2002, 277, 7386-7395.	3.4	29
86	Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?. <i>Pediatric Rheumatology</i> , 2010, 8, 23.	2.1	29
87	Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. <i>Pediatric Rheumatology</i> , 2013, 11, 25.	2.1	27
88	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 521-537.	3.4	27
89	Early Growth Response-1 Is Required for CD154 Transcription. <i>Journal of Immunology</i> , 2006, 176, 811-818.	0.8	26
90	Brain cavernomas associated with en coup de sabre linear scleroderma: Two case reports. <i>Pediatric Rheumatology</i> , 2011, 9, 18.	2.1	26

#	ARTICLE	IF	CITATIONS
91	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	5.6	26
92	Effective gene suppression using small interfering RNA in hard-to-transfect human T cells. <i>Journal of Immunological Methods</i> , 2006, 312, 1-11.	1.4	25
93	Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome?. <i>Journal of Rheumatology</i> , 2015, 42, 1078-1080.	2.0	25
94	Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. <i>Pediatric Rheumatology</i> , 2008, 6, 5.	2.1	24
95	Cancer risk in childhood-onset systemic lupus. <i>Arthritis Research and Therapy</i> , 2013, 15, R198.	3.5	24
96	<i>Akkermansia muciniphila</i> is permissive to arthritis in the K/BxN mouse model of arthritis. <i>Genes and Immunity</i> , 2019, 20, 158-166.	4.1	24
97	HIV-1, NFAT, and Cyclosporin: Immunosuppression for the Immunosuppressed?. <i>DNA and Cell Biology</i> , 2001, 20, 761-767.	1.9	23
98	Corticosteroid-induced spinal epidural lipomatosis in the pediatric age group: report of a new case and updated analysis of the literature. <i>Pediatric Rheumatology</i> , 2011, 9, 5.	2.1	23
99	Condylar Degeneration and Diseases—Local and Systemic Etiologies. <i>Seminars in Orthodontics</i> , 2013, 19, 89-96.	1.4	21
100	A signal achievement in the treatment of arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2229-2232.	6.7	20
101	Treatment of Juvenile Idiopathic Arthritis in the Biologic Age. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 751-766.	1.9	20
102	Pediatric Rheumatology for the Adult Rheumatologist II. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 205-210.	0.9	19
103	Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2499-2509.	6.7	19
104	Results of a multinational survey regarding the diagnosis and treatment of temporomandibular joint involvement in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2014, 12, 6.	2.1	19
105	Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 282-284.	0.9	19
106	Defining the normal appearance of the temporomandibular joints by magnetic resonance imaging with contrast: a comparative study of children with and without juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2018, 16, 8.	2.1	19
107	Host Factor Transcriptional Regulation Contributes to Preferential Expression of HIV Type 1 in IL-4-Producing CD4 T Cells. <i>Journal of Immunology</i> , 2012, 189, 2746-2757.	0.8	18
108	Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. <i>Current Opinion in Pediatrics</i> , 2021, 33, 549-555.	2.0	18

#	ARTICLE	IF	CITATIONS
109	Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children. <i>Biology</i> , 2022, 11, 417.	2.8	16
110	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012, 1, 1.	0.0	15
111	Who Would Have Predicted Multisystem Inflammatory Syndrome in Children?. <i>Current Rheumatology Reports</i> , 2022, 24, 1-11.	4.7	15
112	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis Care and Research</i> , 2022, 74, 505-520.	3.4	15
113	Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2155-2159.	2.0	14
114	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2017, 44, 1484-1486.	2.0	14
115	Severe Neonatal Coronavirus Disease 2019 Presenting as Acute Respiratory Distress Syndrome. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e367-e369.	2.0	14
116	Adolescent Sjogren's syndrome presenting as psychosis: a case series. <i>Pediatric Rheumatology</i> , 2020, 18, 15.	2.1	14
117	Current treatment for chronic arthritis in childhood. <i>Current Opinion in Pediatrics</i> , 2002, 14, 684-687.	2.0	13
118	High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. <i>Pediatric Rheumatology</i> , 2011, 9, 20.	2.1	13
119	Management of temporomandibular joint arthritis in adult rheumatology practices: a survey of adult rheumatologists. <i>Pediatric Rheumatology</i> , 2012, 10, 26.	2.1	13
120	Anaphylaxis to Etanercept in Two Children With Juvenile Idiopathic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 129-131.	0.9	13
121	Reiter syndrome initially misdiagnosed as Kawasaki disease. <i>Journal of Pediatrics</i> , 1996, 128, 366-369.	1.8	12
122	The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target?. <i>Current Opinion in Rheumatology</i> , 2016, 28, 537-543.	4.3	12
123	Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort. <i>ACR Open Rheumatology</i> , 2019, 1, 527-532.	2.1	12
124	Coronavirus is the trigger, but the immune response is deadly. <i>Lancet Rheumatology</i> , The, 2020, 2, e370-e371.	3.9	12
125	Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children. <i>ACR Open Rheumatology</i> , 2021, 3, 820-826.	2.1	11
126	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis and Rheumatology</i> , 2022, 74, 570-585.	5.6	11

#	ARTICLE	IF	CITATIONS
127	Temporomandibular Joint Arthritis in Pediatric Sjögren Disease and Sarcoidosis. <i>Journal of Rheumatology</i> , 2011, 38, 2272-2273.	2.0	10
128	Therapeutic strategies for treating juvenile idiopathic arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102226.	3.5	10
129	Kill or Be Killed. <i>Journal of Immunology</i> , 2015, 194, 5041-5043.	0.8	9
130	Systemic and intra-articular anti-inflammatory therapy of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. <i>Seminars in Orthodontics</i> , 2015, 21, 125-133.	1.4	9
131	Macrophage Activation Syndrome. , 2018, , 151-182.		9
132	Drs. Cron and Chatham reply. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200492.	2.0	9
133	Discrete Choice Experiment on a Magnetic Resonance Imaging Scoring System for Temporomandibular Joints in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 308-316.	3.4	9
134	Overexpression of octamer transcription factors 1 or 2 alone has no effect on HIV-1 transcription in primary human CD4 T cells. <i>Virology</i> , 2004, 321, 323-331.	2.4	8
135	Temporomandibular joint arthritis in juvenile idiopathic arthritis: the last frontier. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 273-286.	0.3	8
136	Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. <i>Pediatric Rheumatology</i> , 2017, 15, 79.	2.1	8
137	Characteristics of coexisting localized scleroderma and inflammatory arthritis. <i>European Journal of Rheumatology</i> , 2020, 7, 67-71.	0.6	8
138	Effect of COVID-19 on anakinra-induced remission in homozygous <i>STX11</i> hemophagocytosis lymphohistiocytosis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28897.	1.5	7
139	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. <i>Journal of Pediatrics</i> , 2021, 235, 196-202.	1.8	7
140	Who, what, and when—effective therapy for severe COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e2-e3.	3.9	7
141	No perfect therapy for the imperfect COVID-19 cytokine storm. <i>Lancet Rheumatology</i> , The, 2022, 4, e308-e310.	3.9	7
142	Freshly isolated Thy-1+ dendritic epidermal cells express T cell receptor β -CD3. <i>Journal of Dermatological Science</i> , 1990, 1, 459-464.	1.9	6
143	Pediatric Rheumatology for the Adult Rheumatologist I. <i>Journal of Clinical Rheumatology</i> , 2005, 11, 21-33.	0.9	6
144	Sarcoidosis in a young child with Alagille syndrome: a case report. <i>Pediatric Rheumatology</i> , 2012, 10, 32.	2.1	6

#	ARTICLE	IF	CITATIONS
145	Changes in Body Mass Index in Children with Juvenile Idiopathic Arthritis Treated with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 113-118.	2.0	6
146	Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year. <i>Pediatric Rheumatology</i> , 2018, 16, 16.	2.1	6
147	Defining the scourge of COVID-19 hyperinflammatory syndrome. <i>Lancet Rheumatology</i> , The, 2020, 2, e727-e729.	3.9	6
148	Drs. Cron and Chatham reply. <i>Journal of Rheumatology</i> , 2020, 47, 1590-1591.	2.0	6
149	Recent progress in the treatment of non-systemic juvenile idiopathic arthritis. <i>Faculty Reviews</i> , 2021, 10, 23.	3.9	6
150	Reactive arthritis of the temporomandibular joints and cervical spine in a child. <i>Pediatric Rheumatology</i> , 2007, 5, 4.	2.1	5
151	Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteins. <i>Virology</i> , 2018, 516, 21-29.	2.4	5
152	Alagille Syndrome and Chronic Arthritis: An International Case Series. <i>Journal of Pediatrics</i> , 2020, 218, 228-230.e1.	1.8	5
153	Intravenous anakinra for cytokine storm syndromes – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e522-e523.	3.9	5
154	Drs. Cron and Chatham reply. <i>Journal of Rheumatology</i> , 2020, 47, 1723.2-1723.	2.0	5
155	Successful treatment of pediatric Tolosa-Hunt syndrome with adalimumab. <i>European Journal of Rheumatology</i> , 2020, 7, 82-84.	0.6	5
156	A Rare STXBP2 Mutation in Severe COVID-19 and Secondary Cytokine Storm Syndrome. <i>Life</i> , 2022, 12, 149.	2.4	5
157	Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 953.	0.8	5
158	IL-1 Family Blockade in Cytokine Storm Syndromes. , 2019, , 549-559.		4
159	Bacteria-Associated Cytokine Storm Syndrome. , 2019, , 307-317.		4
160	Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children. <i>Current Opinion in Rheumatology</i> , 0, Publish Ahead of Print, .	4.3	4
161	Chronic arthritis without uveitis in velocardiofacial syndrome. <i>Journal of Pediatrics</i> , 2006, 149, 281.	1.8	3
162	Intensive care requirement, rather than degree of serum ferritin elevation, predicts mortality in macrophage activation syndrome. <i>Pediatric Critical Care Medicine</i> , 2012, 13, 616.	0.5	3

#	ARTICLE	IF	CITATIONS
163	Weathering a Macrophage Storm. <i>Journal of Rheumatology</i> , 2017, 44, 970-972.	2.0	3
164	One-two punch of cytokine storm syndrome. <i>Blood</i> , 2020, 136, 645-646.	1.4	3
165	Management of juvenile idiopathic arthritis: Preliminary qualitative findings from the National Dental Practice-Based Research Network. <i>Journal of the World Federation of Orthodontists</i> , 2021, 10, 70-73.	2.3	3
166	Precision medicine in juvenile idiopathic arthritis—has the time arrived?. <i>Lancet Rheumatology</i> , The, 2021, 3, e808-e817.	3.9	3
167	Hyperferritinemia Wins Again: Defining Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 1355-1357.	2.0	2
168	Comparison of the condyle-fossa relationship and resorption between patients with and without Juvenile Idiopathic Arthritis (JIA). <i>Journal of Oral and Maxillofacial Surgery</i> , 2021, , .	1.2	2
169	A 3D CBCT Analysis of Airway and Cephalometric Values in Patients Diagnosed with Juvenile Idiopathic Arthritis Compared to a Control Group. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4286.	2.5	2
170	Response to: “Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease” by Sato et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e62-e62.	0.9	1
171	1.5 Decades Later: Bearing fruits from the ACR/EULAR exchange Program. <i>Pediatric Rheumatology</i> , 2011, 9, 14.	2.1	0
172	Inhibition of NFAT2 expression by FOXP3. <i>FASEB Journal</i> , 2008, 22, 848.27.	0.5	0
173	Macrophage Activation Syndrome. , 2017, , 275-292.		0
174	202: SARS-CoV-2 Acquisition Post Cardiac Surgery in a Neonate. <i>Critical Care Medicine</i> , 2021, 49, 86-86.	0.9	0
175	Surgical Management of Juvenile Idiopathic Arthritis Related Dentofacial Deformities. <i>Face</i> , 0, , 273250162110696.	0.2	0